19:03 , Mar 20, 2019 |  BC Extra  |  Clinical News

Cytokinetics gets bump after DMC says CVOT should proceed

Cytokinetics added $1.63 (19%) to $10.19 on Wednesday after it said a DMC recommended the Phase III GALACTIC-HF cardiovascular outcomes trial of omecamtiv mecarbil continue without changes following a planned interim analysis, which included a...
21:35 , Mar 18, 2019 |  BC Extra  |  Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for...
22:43 , Mar 6, 2019 |  BC Extra  |  Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

UCB Ventures hired Alicia Irurzun-Lafitte as a partner. She was a principal at M Ventures, the corporate venture fund of Merck KGaA (Xetra:MRK). GlycoMimetics Inc. (NASDAQ:GLYC) said Chairman Jim Barrett will retire from the board....
22:30 , Mar 5, 2019 |  BC Extra  |  Politics & Policy

PhRMA, BIO on board with NIH's HEAL committee

NIH said it partnered with PhRMA and BIO to form a committee to help guide its Helping to End Addiction Long-term Initiative to address pain and addiction. Industry, academics and patients will be represented on...
00:22 , Mar 5, 2019 |  BC Extra  |  Company News

Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors. Months of...
19:11 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

New bacteriophage-related therapeutic strategies for colitis and colorectal cancer

DISEASE CATEGORY: Cancer; gastrointestinal INDICATION: Colorectal cancer; colitis Patient sample and mouse studies suggest an E. coli bacteriophage cocktail could help treat bacteria-aggravated colorectal cancer and blockade of host-bacteriophage interactions via inhibition of IFNγ or...
19:56 , Mar 1, 2019 |  BC Week In Review  |  Company News

Jury upholds three Repatha patent claims

A jury upheld the validity of three of the five asserted claims covering two U.S. patents for PCSK9 inhibitor Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN). The jury found two of the claims of U.S. Patent...
01:33 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Alder submits BLA for migraine therapy, raises $130M in follow-on

After submitting its first BLA to FDA on Feb. 22, Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) raised $130 million in a bumped-up follow-on late Feb. 27. Alder submitted the BLA for eptinezumab, a mAb against calcitonin-related gene...
06:27 , Feb 27, 2019 |  BioCentury  |  Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
23:56 , Feb 25, 2019 |  BC Extra  |  Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...